User Tools

Site Tools


Deep vein thrombosis

Deep venous thrombosis (DVT) is a venous return disorder caused by abnormal coagulation of blood in the deep venous system and is a common complication after surgery. The main hazard of DVT is acute stage thrombus shedding, which can cause a pulmonary embolism (PE) and acute respiratory distress syndrome when the blood flow blocks the pulmonary artery

The formation of a blood clot (thrombus) within a deep vein, is predominantly in the legs, and contributes significantly to the morbidity and mortality of neurosurgical patients.


An average incidence of DVT of 24 percent was found among 474 untreated control neurosurgical patients 1).

However, based on the current literature, the incidence of DVT varies in patients with different diseases. For example, the incidence of DVT is 1.5–18% and 32% in patients with a subarachnoid hemorrhage and in patients with a brain tumor, respectively 2) 3).

In addition, the incidence of DVT after craniotomy has been reported to be as high as 50%, and using a threshold of 2 mg/L, D-dimer levels indicate venous thromboembolism with a high degree of sensitivity and specificity in patients who have undergone craniotomy 4).

In a study lower extremity DVT was a common complication following craniotomy in the enrolled Chinese neurosurgical patients. Multiple factors were identified as predictive of DVT in neurosurgical patients, including the presence of a tumor, an age greater than 50 years, hypertension, and immobility 5).

Taniguchi et al. reported an incidence of PE in neurosurgical patients with DVT of 60% 6) moreover, DVT may lead to a PE, which is lethal in up to 50% of affected neurosurgical patients 7) 8).

The rate of lower extremity DVT after neurosurgery was 31.1% in the series of Guo et al 9).

Risk factors


Currently, color flow duplex scanning performed by skilled operators provides the most practical and cost-effective method for assessing DVT of the proximal and distal lower extremity veins.

Unfortunately, most duplex ultrasound-based algorithms for the diagnosis of DVT, and some vascular laboratories, still do not include an initial ultrasound evaluation of the calf veins as part of their routine evaluation for DVT, even in symptomatic patients. This is largely the result of outdated perceptions of the inaccuracy of ultrasound evaluation of DVT isolated to the calf veins. Failure to perform a complete initial examination necessitates serial ultrasound examinations or alternative strategies to detect possible extension of venous thrombi initially isolated to the calf veins. Such strategies are inefficient, and unlikely to be cost effective, compared with the modern practice of a single stand-alone color flow duplex study of the proximal and distal lower extremity veins in patients with suspected DVT.

According to the Diagnosis and Treatment Guide of DVT created previously 10) 11) The diagnosis of DVT should be confirmed through auxiliary examinations, including Doppler ultrasound, plasma D-dimer, confidential interval venography, magnetic resonance imaging venography and angiography, etc.

The Doppler ultrasound diagnostic points of DVT are as follows: (1) The probe pressurized venous lumen is not completely closed; (2) the diameter of the embolization segment vein widens obviously, and the thrombosis echo within the lumen has varying degrees of intensity; (3) color Doppler ultrasound provides color flow imaging during embolization that indicates that the vein is thinned or that there is no blood flow; (4) pulse Doppler shows no blood spectrum in the thrombus segment, and the blood spectrum of the distal thrombus does not change with respiration; and (5) Valsalva test is abnormal.



Treatment is recommended for both proximal and symptomatic distal (isolated calf) DVT. If anticoagulation cannot be administered or is contraindicated for calf DVT, then the recommendations are for serial noninvasive studies over the next 10 to 14 days to assess for proximal progression of the thrombus 12).


Venous thromboembolism.

Non-specific signs may include pain, swelling, redness, warmness, and engorged superficial veins. Pulmonary embolism, a potentially life-threatening complication, is caused by the detachment (embolization) of a clot that travels to the lungs.

Together, DVT and pulmonary embolism constitute a single disease process known as venous thromboembolism. Post-thrombotic syndrome, another complication, significantly contributes to the health-care cost of DVT. Prevention options for at-risk individuals include early and frequent walking, calf exercises, anticoagulants, aspirin, graduated compression stockings, and intermittent pneumatic compression.

In 1856, German pathologist Rudolf Virchow postulated the interplay of three processes resulting in venous thrombosis, now known as Virchow's triad: a decreased blood flow rate (venous stasis), increased tendency to clot (hypercoagulability), and changes to the blood vessel wall. DVT formation typically begins inside the valves of the calf veins, where the blood is relatively oxygen deprived, which activates certain biochemical pathways. Several medical conditions increase the risk for DVT, including cancer, trauma, and antiphospholipid syndrome. Other risk factors include older age, surgery, immobilization (as with bed rest, orthopedic casts, and sitting on long flights), combined oral contraceptives, pregnancy, the postnatal period, and genetic factors such as a non-O blood type. The frequency of occurrence (incidence) increases dramatically from childhood to old age; in adulthood, about 1 in 1000 adults develops DVT annually.

Case series

Medical records of Japanese adult patients with craniotomy for brain tumor were reviewed. In addition to clinical variables including patients' age, sex, body mass index, previous history of DVT, leg paresis, medications, tumor histology, surgical factors, adjuvant therapy, infection, and duration of post-operative immobilization and hospitalization, plasma D-dimer levels were measured at pre-surgery (baseline), on post-operative day (POD) one to 30 and during adjuvant therapy, and were compared between patients with and without DVT.

Thirteen of 61 patients (21.3%) had DVT after surgery with mechanical prophylaxis. All DVTs were asymptomatic. Multivariate analyses found post-operative infection (odds ratio, 12.15; 95% confidence interval, 1.09-134.98; P = 0.03) to be a sole independent risk factor for DVT. D-dimer levels were not significantly different between patients with and without DVT at baseline and POD 1-30, but were significantly elevated during adjuvant therapy in patients with DVT (P = 0.03).

Not a few Japanese patients developed DVT after brain tumor surgery with mechanical prophylaxis, and patients with infection should be carefully monitored for post-operative DVT 13).

There is a common belief that the administration of anticoagulants to patients with brain tumors is contraindicated. Between 1982 and 1986, 50 patients with deep venous thrombosis and pulmonary emboli and brain tumors were examined and treated. Twenty-four patients received an inferior vena cava Greenfield filter and 25 patients were treated with anticoagulants. One patient was terminal and received no therapy. Patients in each group were similar with regard to age, sex, primary tumor, computed tomographic findings, and ultimate outcome. At the time of diagnosis, all patients had a residual tumor and most had significant cerebral edema and midline shift. There were no complications in the group receiving Greenfield filters. One patient had a pulmonary embolus after the filter was placed and later required anticoagulant therapy. In the group receiving anticoagulants, one patient had focal intraventricular bleeding observed incidentally on computed tomographic scan one month after beginning anticoagulant therapy and was totally asymptomatic. One patient had gastrointestinal tract bleeding five days after beginning anticoagulant therapy with heparin sodium, and the therapy was therefore discontinued. No other patient had significant bleeding. In view of these findings, a reevaluation of anticoagulant therapy in patients with central nervous system tumors is warranted 14).

Kaufman HH, Satterwhite T, McConnell BJ, Costin B, Borit A, Gould L, Pruessner J, Bernstein D, Gildenberg PL. Deep vein thrombosis and pulmonary embolism in head injured patients. Angiology. 1983 Oct;34(10):627-38. PubMed PMID: 6226216 15)

Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998;339:80–5.
Prell J, Rachinger J, Smaczny R, Taute BM, Rampp S, Illert J, et al. D-dimer plasma level: A reliable marker for venous thromboembolism after elective craniotomy. J Neurosurg. 2013;119:1340–6.
Ray WZ, Strom RG, Blackburn SL, Ashley WW, Sicard GA, Rich KM. Incidence of deep venous thrombosis after subarachnoid hemorrhage. J Neurosurg. 2009;110:1010–4.
Kim GH, Hahn DK, Kellner CP, Komotar RJ, Starke R, Garrett MC, et al. The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin. J Neurosurg. 2009;110:50–7.
5) , 9)
Guo F, Shashikiran T, Chen X, Yang L, Liu X, Song L. Clinical features and risk factor analysis for lower extremity deep venous thrombosis in Chinese neurosurgical patients. J Neurosci Rural Pract. 2015 Oct-Dec;6(4):471-6. doi: 10.4103/0976-3147.169801. PubMed PMID: 26752303; PubMed Central PMCID: PMC4692000.
Taniguchi S, Fukuda I, Daitoku K, Minakawa M, Odagiri S, Suzuki Y, et al. Prevalence of venous thromboembolism in neurosurgical patients. Heart Vessels. 2009;24:425–8.
Khaldi A, Helo N, Schneck MJ, Origitano TC. Venous thromboembolism: Deep venous thrombosis and pulmonary embolism in a neurosurgical population. J Neurosurg. 2011;114:40–6.
Hamilton MG, Hull RD, Pineo GF. Venous thromboembolism in neurosurgery and neurology patients: A review. Neurosurgery. 1994;34:280–96.
Dermody M, Alessi-Chinetti J, Iafrati MD, Estes JM. The utility of screening for deep venous thrombosis in asymptomatic, non-ambulatory neurosurgical patients. J Vasc Surg. 2011;53:1309–15.
Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2010. A National Clinical Guideline Scottish Intercollegiate Guidelines Network (SIGN). Prevention and management of venous thromboembolism. A national clinical guideline; pp. 1–101.
Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001; 119 (suppl 1): 176S–193S.
Nakano F, Matsubara T, Ishigaki T, Hatazaki S, Mouri G, Nakatsuka Y, Suzuki H. Incidence and risk factor of deep venous thrombosis in patients undergoing craniotomy for brain tumors: A Japanese single-center, retrospective study. Thromb Res. 2018 Mar 27;165:95-100. doi: 10.1016/j.thromres.2018.03.016. [Epub ahead of print] PubMed PMID: 29605752.
Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med. 1987 Dec;147(12):2177-9. PubMed PMID: 3500686.
Kaufman HH, Satterwhite T, McConnell BJ, Costin B, Borit A, Gould L, Pruessner J, Bernstein D, Gildenberg PL. Deep vein thrombosis and pulmonary embolism in head injured patients. Angiology. 1983 Oct;34(10):627-38. PubMed PMID: 6226216.
deep_vein_thrombosis.txt · Last modified: 2019/09/25 22:23 by administrador